Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: Findit who wrote (58603)	5/8/2007 4:32:25 PM
From: hotlinktuna	Respond to of 59879

I think you did well Jim on your choice to take the small gain on VION...looking a bit lower in AH here I see after earnings showing a larger loss than same Q last year...I added PAE at 2.52 -.23 and a beginning position in a cheapie uranium CALVF at 1.56 and it closed at .152 I think...will average down low .14's if they come...best of luck! I still believe CPNE will take off one of these days but it surely is testing my patience....LOL! tuna

To: Findit who wrote (58603)	5/8/2007 4:41:22 PM
From: lexi2004	Read Replies (1) \| Respond to of 59879

Vion Reports 2007 First Quarter Results Tuesday May 8, 4:15 pm ET ====Yes, loss greater per share than before, but read carefully where they spent it. I usually never object to meaningful spending on R&D or things of that nature.... NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION - News) today announced results for the three-month period ended March 31, 2007. ADVERTISEMENT The Company reported a net loss of $8.0 million, or $0.12 per share, for the three-month period ended March 31, 2007, compared to a net loss of $6.0 million, or $0.09 per share, for the same period in 2006. Weighted-average common shares outstanding for the three months ended March 31, 2007 and 2006 were 66.4 million and 66.2 million, respectively. Total operating expenses were $7.9 million and $6.5 million for the three months ended March 31, 2007 and 2006, respectively. The increase in operating expenses was primarily due to higher total research and development expenses resulting from (i) late-stage clinical development of Cloretazine® (VNP40101M), including higher spending for clinical trials and development costs in support of a potential registration filing; (ii) preclinical development costs related to the Company's anticancer agent, VNP40541; (iii) stock-based compensation expense; and (iv) a gift to support research projects at a Yale University research laboratory. In addition, sales, general and administrative expenses were higher than the previous period, primarily due to increased stock-based compensation expense and patent fees.

To: Findit who wrote (58603)	5/9/2007 3:14:55 PM
From: hotlinktuna	Read Replies (1) \| Respond to of 59879

Jim and all news of dividend today: TXTG 1.50 now started trading today! This is our dividend shares from one of those companies from a couple of years back that I'm sorry I can't remember the symbol for, but it actually came through FINALLY!! Suggest everyone go to their account and see if they see shares of TXTG as I found today...I already sold all 720 of mine at 1.50 the bid, ask is 1.75 so it might even jump but I'm just happy to reduce that big loss I had on the original stock by about $1k! Best of luck to anyone else you got shares today!! tuna